Thomas Sandgaard is just getting started. The enigmatic “rockstar CEO” of pain management company Zynex Inc (NASDAQ:ZYXI) has worn many hats throughout his career: Sales leader, lead guitarist, football club owner (pro tip: dealing with shareholders is much easier than dealing with sports fans). From the boardroom to the stage, Sandgaard is building a legacy for forward thinking and plain speaking. Just don’t ask him to reflect on it yet. In this wide-ranging interview with Proactive, Sandgaard shares how h ...

ENGLEWOOD, Colo., Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024. Financial results will be issued in a press release prior to the call. Zynex management will host ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

ENGLEWOOD, Colo., Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024. Zynex's fireside chat will be held in person and webcast live on September 10 at 11:30 AM ET at the Lotte New York Palace Hotel in Ne ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

ENGLEWOOD, Colo., Sept. 3, 2024 /PRNewswire/ -- Zynex Inc. (NASDAQ: ZYXI), a leading medical technology company specializing in non-invasive medical devices for pain management and rehabilitation, today announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain re ...

Earnings and guidance disappointed, but the pullback could be an opportunity. The medical equipment company reported earnings last night that, on a headline basis, disappointed mightily. But there were actually some good reasons for the soft numbers, making the pullback in this small-cap stock a potential buying opportunity. In the second quarter, Zynex grew revenue by 11% to $49.9 million with earnings per share (EPS) of $0.04, which was actually down 55% from the $0.09 print in the year-ago quarter. Both ...

Zynex, Inc. (NASDAQ:ZYXI) Q2 2024 Earnings Conference Call July 23, 2024 4:15 AM ET Company Participants Thomas Sandgaard - Chairman, President & Chief Executive Officer Dan Moorhead - Chief Financial Officer Donald Gregg - President, Zynex Monitoring Solutions Quinn Callanan - MZ North America Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex Second Quarter 2024 Earnings Conference Call. At this ...

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on t ...

Revenue Growth - Device revenue increased by $2.2 million or 16% to $15.9 million for the three months ended June 30, 2024, compared to $13.7 million for the same period in 2023[234] - Net revenue increased by $4.9 million or 11% to $49.9 million for the three months ended June 30, 2024, from $45.0 million for the same period in 2023[237] - Net revenue for the six months ended June 30, 2024, increased by $9.3 million or 11% to $96.4 million from $87.1 million for the same period in 2023[237] - Growth in net revenue for the three and six months ended June 30, 2024, was primarily driven by a 20% and 21% increase in device orders, respectively[237] Supply Chain - Approximately 40% of supplies for electrotherapy products were sourced from three significant vendors for the six months ended June 30, 2024, compared to 26% from two vendors in the same period of 2023[236] Acquisitions - The Company acquired 100% of Kestrel Labs, Inc. in December 2021, which specializes in laser-based patient monitoring technology[229] - Kestrel's products, NiCO and HemeOx, are yet to be presented to the U.S. FDA for market clearance[229] Internal Controls - The Company has identified material weaknesses in internal control over financial reporting as of June 30, 2024[242] - Management concluded that the consolidated financial statements present fairly the financial position and results of operations in accordance with U.S. GAAP[123] - There were no changes in internal control over financial reporting that materially affected the controls during the quarter ended June 30, 2024[125]